Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 2Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Mastocytosis, Systemic 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Hairy Cell 1Kidney Neoplasms 1Hodgkin Disease 1Hematologic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Medullary 1Burkitt Lymphoma 1Breast Carcinoma In Situ 1Brain Neoplasms 1Blastic Plasmacytoid Dendritic Cell Neoplasm 1Advanced Cancer 1

Interventions

Tamoxifen 10Chemotherapy, Adjuvant 7Radiotherapy 5Early Intervention, Educational 5Psychiatric Rehabilitation 4Neoadjuvant Therapy 4Letrozole 4Counseling 4Behavior Therapy 4Anastrozole 4Methods 3Mass Spectrometry 3Magnetic Resonance Spectroscopy 3Immunohistochemistry 3Gene Expression Profiling 3Biopsy 3Telemedicine 2Taxes 2Soybean Proteins 2Simvastatin 2Paclitaxel 2Medroxyprogesterone 2Fatty Acids, Omega-3 2Educational Status 2Docosahexaenoic Acids 2Curcumin 2Chromatography, High Pressure Liquid 2Brachytherapy 2telapristone acetate 1ruxolitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Breast Carcinoma In Situ × Ranitidine × Clear all
NCT04862585 2025-08-20

Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel

Ohio State University Comprehensive Cancer Center

Phase 2/3 Completed
130 enrolled 8 charts
Breast

Breast Carcinoma In Situ, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡